Orgenesis Inc. EV/EBITDA

EV/EBITDA of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBITDA growth rates and interactive chart. EV/EBITDA is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation & Amortization (EBITDA). The EV/EBITDA ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBITDA compared to a stock’s historical average or industry can indicate undervaluation.


Highlights and Quick Summary

Current EV/EBITDA of Orgenesis Inc. is 0.0 (as of December 30, 2020)
  • EV/EBITDA for the quarter ending September 29, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly EV/EBITDA decreased by NaN%
  • Annual EV/EBITDA for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual EV/EBITDA for 2019 was 0.0 (a NaN% decrease from previous year)
  • Annual EV/EBITDA for 2018 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBITDA of Orgenesis Inc.

Most recent EV/EBITDAof ORGS including historical data for past 10 years.

Interactive Chart of EV/EBITDA of Orgenesis Inc.

Orgenesis Inc. EV/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0 0.0 0.0
2020 0.0 0.0 0.0 1.69 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0 0.0 0.0
2016 0.0 0.0 0.0 0.0 0.0
2015 0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.